Gilead (GILD)

Learn everything you need to know about Gilead and find links to beginner-friendly guides that show you the best way to invest in it.
Updated: Mar 27, 2023

About Gilead

Copy link to section

What is Gilead?

Copy link to section

Gilead Sciences is a biopharmaceutical company specialising in various therapies for several diseases. Founded in 1987 and headquartered in Foster City, California, Gilead is best known for its research, development, and commercialisation of medicines for diseases including HIV/AIDS, viral hepatitis, cancer, and inflammatory diseases.

How does Gilead make money?

Copy link to section

It makes money by selling pharmaceutical products. This includes medicines and other therapies. It has four main therapeutic areas, including HIV/AIDS, liver diseases, oncology, and respiratory diseases.

It also generates revenue from licensing agreements and partnerships with other companies in the biopharma industry. Gilead also has a pipeline of drugs in the development stage, which can potentially add to its revenue if approved.

What is Gilead’s best selling product?

Copy link to section

Its best selling product is Biktarvy, which is a daily tablet for the treatment of HIV-1 infection. In quarter 4 of 2022, Biktarvy generated $1.95 billion in net product sales, a 9% increase from the previous year. Biktarvy is the most prescribed HIV regimen in the United States.

The company also has a range of other top-selling therapies, including Truvada (for HIV), Veklury (for COVID-19), and Yescarta (for cancer treatment.

Who are the key executives at Gilead?

Copy link to section

Daniel O’Day is Gilead’s currency chairman and chief executive officer. Here are some other members of its executive team.

  • Daniel P. O’Day. Chairman & CEO
  • Andrew D. Dickinson. Exec. VP & CFO
  • Deborah H. Telman. Exec. VP of Corp. Affairs, Gen. Counsel & Corp.
  • Johanna Mercier. Chief Commercial Officer
  • Merdad V. Parsey M.D., Ph.D. Chief Medical Officer
  • Sandra Patterson. Sr. VP, Corp. Controller & Principal Accounting Officer
  • Jacquie Ross C.F.A.. VP of Investor Relations
  • Jyoti K. Mehra Exec. VP of HR
  • Michael Quigley Ph.D. Sr. VP of Research Biology
  • Linda Slanec Higgins Ph.D. Sr. VP & Head of External Innovation

Where can I buy shares in Gilead?

Copy link to section

You can buy Gilead stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.

Are there any other ways to invest in Gilead?

Copy link to section

The simplest way to invest in Gilead is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.

Gilead is part of the Nasdaq index, so you can invest in an ETF that tracks that index, or choose a pharmaceutical ETF that lets you own a basket of related stocks from the same industry.

More about the GILD price

Copy link to section

What is the Gilead stock price today?

Copy link to section

The GILD stock price today is currently $80.36 as of 27 March, 2023. The price of Gilead is up 35.24% over the past 52 weeks. You can use the live Gilead stock chart to track the NASDAQ:GILD price in real time above, or compare the Gilead value today to its past performance using the Gilead financials tab at the top of this page.

What is the 52-week low for Gilead stock?

Copy link to section

The 52-week low for Gilead stock is $57.17. GILD stock is currently 40.91% above the 52-week low.

What is the 52-week high for Gilead stock?

Copy link to section

The 52-week high for Gilead stock is $98.74. GILD stock is currently 10.24%below the 52-week high.

What is the stock forecast for Gilead?

Copy link to section

The average Gilead stock forecast has a price target of $90.15 by the end of 2023. Gilead’s latest financial results, the broader economic outlook, and the amount of competition in the industry all influence these forecasts.

It’s best to take analyst forecasts with a grain of salt but you can use their estimates to help you understand the weight of opinion about a stock.

More stock guides

Copy link to section


Copy link to section
How much is Gilead worth?
When did GILD stock go public?
Who owns the most shares in Gilead?
Who are Gilead’s biggest competitors?
Has GILD stock split?
When are Gilead’s earnings?
Does Gilead pay a dividend?

Latest Gilead news

Copy link to section

Recent Gilead analysis

Copy link to section

Sources & references
Risk disclaimer
James Knight
Editor of Education
James is the lead editor of education for Invezz. He's an avid trader and golfer, who spends an inordinate amount of time watching Leicester City and… read more.